Fluicell

Fluicell EBIT Margin

The EBIT Margin (Operating Margin) of Fluicell (FLUI.ST) as of Nov 20, 2026 is -144.70 %. In the previous year, EBIT Margin (Operating Margin) was -852.18 % — a change of -83.02% (higher).

EBIT Margin

-144.70 %

YoY

-83.02%

Last updated:

EBIT Margin (Operating Margin) of Fluicell is 2025 -144.70 % . EBIT Margin (Operating Margin) of Fluicell was 2024 -852.18 % . It decreases by -83.02% higher compared to the previous year.

Fluicell's operating (EBIT) margin stands at -144.7%, up from -833.8% several years earlier.

The Fluicell EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-1,205.38 SEK
Jan 1, 2019
-750.92 SEK
Jan 1, 2020
-367.34 SEK
Jan 1, 2021
-833.78 SEK
Jan 1, 2022
-668.32 SEK
Jan 1, 2023
-805.24 SEK
Jan 1, 2024
-852.18 SEK
Jan 1, 2025
-144.70 SEK
The Fluicell EBIT Margin history
YEAREBIT MarginYoY
-144.70 %-83.02%
-852.18 %+5.83%
-805.24 %+20.49%
-668.32 %-19.85%
-833.78 %+126.98%
-367.34 %-51.08%
-750.92 %-37.70%
-1,205.38 %+70.53%
-706.84 %+275.06%
-188.46 %-30.68%
-271.86 %-76.70%
-1,166.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

EBIT Margin (Operating Margin) of Fluicell is -144.70 % in 2025.

EBIT Margin (Operating Margin) of Fluicell changed from -852.18 % to -144.70 %, representing a -83.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Fluicell since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Fluicell with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Fluicell

All Key Metrics — Fluicell